Skip to main content
SpringerLink
Log in

Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The in vitro and in vivo metabolism of RWJ-53050, an anxiolytic agent, was investigated after incubation with rat and human hepatic S9 fractions, and human microsomes and 7 microsomes containing individual human CYP isoforms, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in the presence of NADPH-generating system, and a single oral dose administration to dogs (30 mg/kg). Unchanged RWJ-53050 (≥74% of the sample in vitro; ⪯13% in vivo) plus 16 metabolites were profiled, quantified and tentatively identified based on the API-MS and MS/MS data. The formation of RWJ-53050 metabolites are via the 5 pathways: 1.N/O-demethylation, 2. phenylhydroxylation, 3. pyrido-oxidation, 4. dehydration, and 5. conjugation. Pathway 1 formedO-desmethyl-phenyl-RWJ-53050 (M1, <1–12% in vitro & in vivo), O-desmethyl-benzimidazole-RWJ-53050 (M2), and N-desmethyl-RWJ-53050 (M3) (M2 & M3, ⪯3% in vitro & in vivo). Pathway 2 generated hydroxy-benzimidazole-RWJ-53050 (M4), hydroxy-phenyl-RWJ-53050 (M5), and hydroxy-phenyl-M4 (M9) (⪯3% in vitro & in vivo). Pathway 3 formed 2 trace oxidized metabolites, hydroxy-pyrido-RWJ-53050 (M6, ⪯1% in vitro) and oxo-pyrido-RWJ-53050 (M8, <1% in vitro) and in conjunction with pathway 1 produced 2 trace dioxidized metabolites, OH-benzimidazole-M6 (M10) and OH-benzimidazole-M8 (M11) (in vitro). Pathway 4 formed a minor dehydrated metabolite of M6 (M7, 3%, in vitro). Pathway 5 produced 3 in vivo conjugates, Ml-glucuronide (M14,17%), M5-glucuronide (M15,50%), and M5-sulfate (M16,10%). RWJ-53050 is substantially metabolized in vitro in the rat and human, and extensively metabolized in vivo in the dog. formation of oxidized metabolites, Ml, M2, M4, M5 and M9.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maryanoff, B.E., McComsey, D.F., and Ho, W. ( 1993): 3-Oxopyrido[ 1,2- A]benzimidazole-4-carboxyl and4-oxoazepine [l,2-A]benzimidazole-5-carboxyl derivatives useful for treating central system disorders, US Patent 5,639,760

  2. Maryanoff, B.E., Ho, W., McComsey, D.F., Reitz, A.B.. Grous, P.P., Nortey, S.O., Shank, R.P., Dubinsky, B., Taylor, Jr., R.J., and Gardocki, J.F. (1995): Potential anxiolytic agents, pyrido[l,2-o]benzimidazole: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors, J. Med. Chem., 38, 16–20.

    Article  CAS  PubMed  Google Scholar 

  3. Maryanoff, B.E., McComsey, D.F., Ho, W., Shank, R.P., and Dubinsky, B. (1996): Potential anxiolytic agents — II. Improvement of oral efficacy for the pyrido[ 1,2-α]benzimidazole (PBI) class of GABA-A receptor moderators, Bioorg. Med. Chem Lett., 6, 333–338.

    Article  CAS  Google Scholar 

  4. Maryanoff, B.E., Nortey, S.O., McNally, J.J., Sanfilippo, P.J., McComsey, D.F., Dubinsky, B., Shank, R.P., and Reitz, A.B. (1999): Potential anxiolytic agents: 3. novel A-ring modified pyrido[1,2-α]benzimidazole, Bioorg. Med. Chem. Lett., 9, 1547–1552.

    Article  CAS  PubMed  Google Scholar 

  5. Reitz, A.B., Jordan, A.D., Sanfilippo, P.J., and Vaouyios-Smith, A. (1998): US Patent, 5,817,668,6.

  6. Scott, M.K., Demeter, D.A., Nortey, S.O., Dubinsky. B., Shank, R.P., and Reitz, A.B. (1999): 4 New directions in anxiolytic drug research, Prog. Med. Chem., 36, 169–200.

    Article  CAS  PubMed  Google Scholar 

  7. Jordan, A.D., Vaidya, A.H., Rosenthal, D.I., Dubinsky, B., Kordik, C.P., Sanfilippo, P.J., Wu, W. N., and Reitz, A.B. (2002): Potential anxiolytic agents, part 4: novel orally-active N5-substituted pyrido[l,2-α]benzimidazoles with high GABA-A receptor affinity, Bioorg. Med. Chem. Lett., 12, 2381–2386.

    Article  CAS  PubMed  Google Scholar 

  8. Dubinsky, B., Vaidya, A.H., Rosenthal, D.I., Hochman, C, Crooke, J.J., Deluca, S., Devine, A., Cheo-Isaacs, CT., Carter, A.R., Jordan, A.D., Reitz, A.B., and Shank, R.P. (2002): 5-Ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahy droben zo[4,5]imidazo[1,2α]-pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), anew nonbenzodiazepine anxiolytic, J. Pharmacol. Exp. Ther, 303, 777–790.

    Article  CAS  PubMed  Google Scholar 

  9. Wu, W.N., McKown, L.A., and Takacs, A.R. (1998): In vitro metabolism of the anxiolytic agent, RWJ-53050, in rat and human hepatic S9 fractions, The 12th Inter. Sympos. on Microsom. and Drug Oxidat., Abstract No. 108.

  10. Wu, W.N., McKown, L.A., Streeter, A.J., Takacs, A.R., and Reitz, A.B. (1998): Identifcation of metabolites and the cytochrome P450isoforms responsible for the metabolism of an anxiolytic agent, RWJ-53050, in human microsomes, The 12th Inter. Sympos. on Microsom. and Drug Oxidat., Abstract No. 107.

  11. Wu, W.N., McKown, L.A., and Reitz, A.B. (2001): In vivo metabolism of the anxiolytic agent, RWJ-53050, in the dog, The 6th Internat.ISSX Meeting, Abstract No. 242, Drug Metab. Rev, 33, 123.

    Google Scholar 

  12. Wu, W.N., McKown, L.A., Melton, J.L., and Reitz, A.B. (2003): In vitro metabolism of the new anxiolytic agent, RWJ-50172, in rat hepatic S9 fraction and microbial transformation in fungi, Cunninghamella sp., J. Pharm, and Pharmacol., 55, 1099–1105.

    Article  CAS  Google Scholar 

  13. Wu, W.N., McKown, L.A., and Reitz, A.B. (2003): in vitro metabolism of the new anxiolytic agent. RWJ-52763, in human hepatic s9 fraction — api-ms/ms identification of metabolites, J. Pharm, and Biomed. Analy., 31, 95–102.

    Article  Google Scholar 

  14. Wu, W.N., McKown, L.A., and Reitz, A.B., (2004): Human hepatic metabolism of the anxiolytic agent, RWJ-51521 —api-ms/ms identification of metabolites, Europ. J. Drug Metab. and Pharmacok., 29, 257–262.

    CAS  Google Scholar 

  15. Wu, W.N., McKown, L.A., and Reitz, A.B. (2004):: Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic s9 fractions, and in rats, dogs and humans, Europ. J. Drug Metab. and Pharmacok., 29, 263–268.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh & McKean Rds, 19477, Spring House, PA, USA

    Wu-Nan Wu, Linda A. Mckown & Allen B. Reitz

Authors
  1. Wu-Nan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda A. Mckown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allen B. Reitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, WN., Mckown, L.A. & Reitz, A.B. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism. European Journal of Drug Metabolism and Pharmacokinetics 31, 277–283 (2006). https://doi.org/10.1007/BF03190468

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190468

Keywords

Search

Navigation